Background: Pediatric glioblastoma is a malignant disease with an extremely poor clinical outcome. Patients usually suffer from resistance to radiation therapy, so targeted drug treatment may be a new possibility for glioblastoma therapy. Survivin is also overexpressed in glioblastoma. YM155, a novel small-molecule survivin inhibitor, has not been examined for its use in glioblastoma therapy. Methods: The human glioblastoma cell line M059K, which expresses normal DNA-dependent protein kinase (DNA-PK) activity and is radiation-resistant, and M059J, which is deficient in DNA-PK activity and radiation-sensitive, were used in the study. Cell viability, DNA fragmentation, and the expression of survivin and securin following YM155 treatment were examined using MTT (methylthiazolyldiphenyl-tetrazolium) assay, ELISA assay, and Western blot analysis, respectively. Results: YM155 caused a concentration-dependent cytotoxic effect, inhibiting the cell viability of both M059K and M059J cells by 70% after 48 hours of treatment with 50 nM YM155. The halfmaximal inhibitory concentration (IC50) was around 30e35 nM for both cell lines. Apoptosis was determined to have occurred in both cell lines because immunoreactive signals from the DNA fragments in the cytoplasm were increased 24 hours after treatment with 30 nM YM155. The expression of survivin and securin in the M059K cells was greater than that measured in the M059J cells. Treatment with 30 nM YM155, for both 24 and 48 hours, significantly suppressed the expression of survivin and securin in both cell lines.
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Introduction
Brain tumors are one of the most common solid neoplastic disorders that present in children. 1 The death of a pediatric patient with a brain tumor, especially a high-grade glioma, usually results from cancer. 2, 3 Glioblastoma demonstrates the worse therapeutic response among high-grade gliomas, with a very low 5-year survival rate despite aggressive chemotherapy and/or radiation therapy.
4e6 Thus, new strategies for treating glioblastomas should be investigated.
Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in human glioblastoma tissues. 7 Studies have shown that the 3-year survival rate of glioblastoma tissues with positive nuclear survivin expression is zero; thus, survivin may be a useful biomarker for predicting clinical prognosis in patients with glioblastoma. 8 Treatments aimed at inhibiting survivin expression could be a new strategy for the treatment of glioblastomas. However, specific survivin suppressants have not been examined for use in glioblastoma treatments.
A small molecule, YM155 {1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho [2,3-d] imidazolium bromide}, has been identified by highthroughput screening as an inhibitor of the activity of the survivin gene promoter.
14 YM155, as a survivin suppressant, has been shown to inhibit the progression of some neoplasms in vitro and/or in vivo (e.g., prostate cancer 14, 15 and lung cancer). 16, 17 Until now, YM155 has not been studied for its use in glioblastoma therapy. Therefore, we conducted an in vitro study to evaluate the therapeutic effects of YM155 in two glioblastoma cell lines: one cell line that expresses normal DNA-dependent protein kinase (DNA-PK) activity, and another cell line that is deficient in DNA-PK activity. The former is resistant to radiation, whereas the latter is sensitive to radiation. 18 This study's aim was to demonstrate that YM155 exerts potent cytotoxicity through survivin inhibition and induces apoptosis in both of these glioblastoma cell lines.
Materials and Methods

Cell culture
Human glioblastoma cell lines M059J and M059K were obtained from Dr. Shu Jun Chiu (Department of Life Sciences, Tzu Chi University, Hualien, Taiwan). M059J and M059K exhibit deficient DNA-PK and normal DNA-PK activities, respectively. The cells were cultured in F-12/ Dulbecco's modified Eagle medium in combination with 10% fetal bovine serum (FBS) and 1% penicillin plus streptomycin. 19 
MTT cytotoxicity assay
For the cytotoxicity assay, 1.0 Â 10 4 glioblastoma cells per well were seeded onto 96-well plates. After overnight incubation, the cells adhered to the plate. YM155 (Selleck, Houston, TX, USA) at a concentration of 0e50 nM was dissolved in dimethyl sulfoxide (DMSO; J.T. Baker, Phillipsburg, NJ, USA) and incubated for 48 hours. The MTT (methylthiazolyldiphenyl-tetrazolium bromide; Sigma, St. Louis, MO, USA) assay was then performed, using the protocol described in a previous study. 20 
DNA fragmentation assay
The Cell Death Detection ELISA PLUS (Roche, Mannheim, Germany) assay kit was used to differentiate apoptotic and necrotic glioblastoma cells after treatment with YM155. Twenty-four hours after drug treatment, both supernatants of the cultured medium and the cytoplasmic fraction from 2.0 Â 10 4 cells were collected in 24-well dishes. The optical density (OD) value at 405 nm, which represents the extent of DNA fragmentation, was measured.
Western blot analysis
After YM155 treatment, the expression levels of survivin and securin in the glioblastoma cells were detected using Western blot analysis. The procedures we followed were described in our previous report. 20 Primary antibodies, including anti-survivin (#2808; Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-securin (ab3305; Abcam, Cambridge, MA, USA), were used. The expression of a-tubulin (anti-a-tubulin, sc-8305; Santa Cruz, CA, USA) was used as the internal standard. The intensity of the immunoreactive proteins was calculated using NIH software ImageJ V.1.40. The intensity ratio, which was calculated by dividing the intensity of survivin or securin to that of a-tubulin, was used to compare the effects of YM155 treatment.
Statistical analysis
Data are presented as the mean AE standard error of mean (SEM) and were analyzed using the Student t test. In all cases, p < 0.05 was considered statistically significant and is labeled using an asterisk (*) in the figures. Double and triple asterisks (** and ***) in the figures indicated p < 0.01 and p < 0.005, respectively.
Results
Cytotoxic effects of YM155 on glioblastoma cells
After 48 hours of treatment, YM155 elicited potent cytotoxicity in a concentration-dependent manner in both DNA-PK-deficient M059J ( Figure 1A ) and DNA-PK-normal M059K ( Figure 1B) human glioblastoma cells. The half-maximal inhibitory concentration (IC50) was about 30e35 nM (Table 1) . YM155 exerted significant cytotoxicity on both cell lines when the concentrations were > 10 nM. The viabilities of the M059J and M059K cells were not Figure 1 Cytotoxic effects of YM155 on glioblastoma cells. The viability of (A) M059J (n Z 3) and (B) M059K (n Z 3) cells was measured using an MTT assay 48 hours after treatment with YM155. The viability ratio is the ratio of the optical density value obtained from the drug-treated sample divided by that of the control sample that was only treated with phosphate-buffered saline. significantly different at each concentration of YM155 (5e50 nM; Table 1 ).
YM155 induces apoptosis in glioblastoma cells
To determine the characteristics of the cytotoxicity that is mediated by YM155 in glioblastoma cells, a DNA fragmentation ELISA assay was carried out. Low basal levels of DNA fragments bound to anti-histone plus anti-DNA antibodies were detected in the culture medium of the M059J and M059K cells 24 hours after treatment with 30 nM YM155. A significantly large amount of cytoplasmic DNA fragments was found after treating the M059J and M059K cells with 30 nM YM155 in comparison with the control ( Figure 2A and 2B) . These results indicated that YM155 induces apoptosis in M059J and M059K glioblastoma cells.
Expression of survivin in glioblastoma cells after YM155 treatment
As shown in Figure 3A and 3B, survivin expression in the M059J cells was inhibited by about 80% at 24 hours after treatment with 30 nM YM155, and almost the complete inhibition (96.6%) of survivin expression was noted 48 hours after treatment. Figure 3C shows that the expression of immunoreactive survivin in M059K cells was more abundant (1.56-fold higher, p Z 0.01) than that measured in M059J cells. Survivin expression in M059K cells was also significantly inhibited 24 hours after treatment with 30 nM YM155, and > 80% inhibition was noted 48 hours later ( Figure 3C and 3D) .
Expression of securin in glioblastoma cells after YM155 treatment
Comparisons of the immunoreactive signals between the two glioblastoma cell lines shows that securin was much more strongly expressed in M059K cells (2.56-fold higher, p Z 0.01) than M059J cells ( Figure 4A and 4C ). Securin expression in the M059J cells ( Figure 4A and 4B) and M059J cells ( Figure 4C and 4D) was significantly inhibited at 24 and 48 hours after treatment with 30 nM YM155.
Discussion
DNA-PK is a nuclear protein kinase that consists of a catalytic subunit (DNA-PKcs) and a heterodimeric DNA targeting subunit (Ku). 21 DNA-PK is directly activated by doublestranded DNA after exposure to ionizing radiation (IR), 22 and it plays an important role in the repair of doublestranded breaks via nonhomologous end-joining (NHEJ) and V(D)J recombination. 23 Cells that are deficient in DNA-PK activity are extremely sensitive to IR. 24 Conversely, increased expression or activity of DNA-PK promotes cancer cell resistance to chemotherapeutic agents or IR. 25, 26 Thus, the M059K human glioblastoma cell line with normal DNA-PK may be a good cell model for investigating new treatment strategies against radiation-resistant glioblastoma.
Our results show that the novel survivin inhibitor YM155 elicits cytotoxicity in the glioblastoma cell lines M059K and M059J, indicating that DNA-PK is not involved in survivin inhibition-induced apoptosis of glioblastoma cells. Capalbo et al described the interaction between nuclear survivin and DNA-PKs following exposure to irradiation, demonstrating that survivin knockdown by RNAi impairs the repair of double-stranded DNA breaks. 27 Survivin-depleted cells also present with decreased DNA-PK activities. 27 This evidence explains why survivin expression in radiationresistant M059K cells was greater than that measured in radiation-sensitive M059J cells in this study. This is consistent with the observation that survivin mediates radioresistance in cancer cells. 28, 29 Survivin is undetectable in normally differentiated human adult tissues. 30 Thus, the targeting of survivin inhibition may not influence the functioning of normal cells. Knockdown of survivin by shRNA delays the growth of glioblastoma xenografts in nude mice. 31 However, the clinical applications of genetic knockdowns may not be feasible in the near future. A few phase I/II clinical trials on the use of YM155 in cancer therapies have already been reported, and these treatments were well tolerated by patients with minimal adverse effects such as fatigue, nausea, and pyrexia. 32e34 Thus, YM155 may offer a new hope for glioblastoma patients, including those with radiation resistance.
Human securin is identical to the product of PTTG (pituitary tumor-derived transforming gene), and the overexpression of securin has been observed in several human cancers other than pituitary tumors. 35e37 The securin that is expressed in the nuclei was originally found to be an inhibitor of premature sister chromatid separation and a potential activator of transcription, but recently it has also been found to mediate tumor invasiveness and recurrence. 38 Until now, there have been no studies that have investigated the expression of securin in human glioblastoma cells and tissues, and our results provide the first results. In our previous report, concomitantly decreased expression of survivin and securin in bladder cancer cells was noted after TrkB antibody treatment. 39 Chao and Liu have also demonstrated that the transfection of survivin siRNA significantly induces apoptosis and decreases the levels of survivin and securin proteins in A549 cells. 40 Thus, the decreased expression of securin and elevated apoptosis following YM155 treatment observed in our study is consistent with previous studies. Furthermore, Chen et al reported that securin mediates radiosensitivity. 41 Thus, the higher expression level of securin that was observed in M059K cells in comparison with M059J cells may at least partly explain why M059K cells exhibit radiation resistance.
In conclusion, survivin inhibition by YM155 elicits potent cytotoxicity in human glioblastoma cells via DNA-PKindependent mechanisms. YM155 could be used as a new therapeutic drug for treating glioblastomas, including those that are resistant to radiation.
